Although monoclonal EGFR-TKIs, such as cetuximab, are commonly used in the clinical treatment of CRC [41], there are therapeutic limitations and these drugs are ineffective in patients with RAS gene mutations [42–44]. Here, EGFR is linked to colorectal carcinoma.